Given the high frequency of FLT3 mutations in AML and their correlation with poor prognosis, in recent years, extensive research focusing on the development of targeted therapies was conducted, aiming to enhance patient outcomes. The gene discussed is FLT3; the disease is acute myeloid leukemia.